摘要
目的评价美洛西林及其美洛西林钠舒巴坦钠治疗泌尿系统感染的成本-效果。方法将医院泌尿系统感染患者128例随机分为两组,分别给予美洛西林钠和美洛西林钠舒巴坦钠治疗,运用药物经济学成本-效果分析法计算每例治疗成本,并进行分析和评价。结果美洛西林钠组和美洛西林钠舒巴坦钠组的总有效率分别为84.62%和98.41%,差异有统计学意义(P<0.05)。不良反应发生率为4.62%和4.76%;以临床总有效率计算成本-效果比分别为14.42和14.36,差异无统计学意义(P>0.05)。结论从药物经济学角度,美洛西林钠舒巴坦钠治疗泌尿系统感染更具成本-效果优势。
Objective To evaluate the economic benefit of mezlocillin injection versus mezlocillin sulbactam injection in the treatment of urinary tract infections.Methods 128 patients with urinary tract infections were randomly divided into mezlocillin group or mezlocillin sulbactam group.Those patients were evaluated by pharmacoeconomics cost-effectiveness analysis.Results Efficacy rate of two groups were 84.62% and 98.41% respectively.There was significant difference between the two groups（P0.05）.The incidence of adverse reactions in two groups were 4.62% and 4.76%,and the cost-effectiveness（C/E） were 14.42 and 14.36.There were no significant differences between the two groups（P0.05）.Conclusion According to the cost-effectiveness analysis,mezlocillin sulbactam injection has cost-effectiveness advantage in the treatment of urinary tract infections.
出处
《重庆医学》
CAS
CSCD
北大核心
2012年第36期3830-3832,共3页
Chongqing medicine
基金
国家十二五"重大新药创制"科技重大专项(2011ZX09201-101-3
2011zx09401-301-4)
重庆市卫生局医学科学技术研究项目(2010-2-398)
关键词
美洛西林
泌尿道感染
经济学
药物
美洛西林钠舒巴坦钠
成本-效果分析
mezlocillin
urinary tract infections
economics
pharmaceutical
mezlocillin sulbactam
cost-effectiveness analysis
